A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2018
At a glance
- Drugs Tremelimumab (Primary) ; Durvalumab
- Indications Adenocarcinoma; Bladder cancer; Breast cancer; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 19 Jun 2018 Planned End Date changed from 5 Oct 2018 to 24 Dec 2018.
- 19 Jun 2018 Planned primary completion date changed from 20 Mar 2018 to 24 Dec 2018.
- 20 Jan 2018 Results (n= 20; As of April 5, 2017) in patients with metastatic pancreatic ductal adenocarcinoma, presented at the 2018 Gastrointestinal Cancers Symposium